brefeldin
bfa
uniqu
fungal
metabolit
lacton
ring
exhibit
variou
biolog
action
includ
antitumor
antifung
antivir
activ
present
studi
mous
lb
cell
treat
variou
concentr
interferon
ifn
andor
bfa
overnight
infect
encephalomyocard
viru
emcv
remov
ifn
bfa
dose
bfa
neither
inhibit
metabol
cell
infect
emcv
decreas
ifninduc
antivir
activ
emcv
demonstr
viru
titer
supernat
sinc
synthetas
doublestrand
rna
dsrna
depend
protein
kinas
pkr
suggest
involv
antivir
action
ifn
emcv
activ
investig
lb
cell
bfa
treatment
northern
blot
analysi
situ
hybrid
show
decreas
mrna
oligoadenyl
synthetas
bfa
treatment
bfa
also
inhibit
activ
synthetas
depend
rnase
phosphoryl
pkr
cellular
extract
indic
bfa
may
exert
inhibitori
effect
theltranscript
posttranscript
level
studi
report
new
biolog
action
bfa
demonstr
bfa
antagon
antivir
action
ifn
inhibit
ifninduc
enzymat
pathway
studi
also
suggest
pkr
import
antivir
activ
ifn
emcv
brefeldin
bfa
fungal
metabolit
antibiot
contain
macrocyt
lacton
ring
antivir
antibacteri
antifung
activ
harriet
al
tamura
et
al
morpholog
studi
shown
bfa
caus
disassembl
golgiapparatu
tion
variou
protein
variou
cell
type
fujiwara
et
al
misumi
et
al
magner
papagiann
bfa
inhibit
glycoprotein
secret
vsvinfect
bhk
cell
takatsuki
tamura
process
secret
envelop
glycoprotein
human
immunodefici
viru
cell
infect
hiviii
b
strain
lead
inhibitior
viral
particl
format
pal
et
al
bfa
revers
arrest
assembl
releas
variou
viral
particl
includ
herp
simplex
viru
cheung
et
al
pseudorabi
viru
wheali
et
al
punta
toro
viru
chen
et
al
bfa
use
studi
fold
assembl
transport
intramolecular
interact
envelop
protein
earl
et
al
interferon
ifn
protein
glycoprotein
potent
biolog
function
includ
antivir
growth
inhibitori
immunoregulatori
pestka
et
al
adam
hamilton
sever
studi
staeh
samuel
gupta
et
al
rice
et
al
hovanessian
et
al
galabru
hovanessian
shown
ifn
treatment
associ
induct
two
doubl
strand
rnadepend
enzym
oligoadenyl
synthetas
protein
kinas
biochem
pathway
implic
ifnmedi
inhibit
number
virus
studi
report
paper
show
low
nontox
dose
bfa
effect
emcv
abolish
antivir
activ
ifn
emcv
lb
cell
inhibit
activ
ifninduc
synthetas
pkr
depend
rnase
studi
report
new
biolog
action
bfa
inhibit
ifninduc
biochem
enzymat
pathway
involv
antivir
activ
ifn
emcv
subclon
eleven
deriv
mous
lb
cell
line
origin
obtain
dc
burk
univers
warwick
coventri
uk
singl
cell
clone
method
singh
et
al
cell
maintain
eagl
mem
emem
supplement
fetal
bovin
serum
emcv
origin
obtain
c
buckley
niaid
nih
bethesda
md
usa
plaqu
purifi
passag
multipl
tcidsocel
viru
stock
assay
determin
cytopatholog
effect
epe
lb
cell
titer
tcidsocel
recombin
murin
ifnfl
obtain
toray
industri
japan
bfa
purchas
epicent
madison
wi
polyionosinicpolycytidyl
acid
poli
c
doubl
strand
rna
purchas
pharmacia
lbk
biotechnolog
usa
p
dctp
cimmol
dcpt
cimmol
atp
cimmol
suppli
dupontnen
boston
fig
pcr
amplif
ifnfl
poli
c
without
bfa
treat
l
b
cell
rna
prepar
normal
poli
ctreat
poli
c
bfatreat
cell
revers
transcrib
amplifi
ifnfl
gene
amplif
gapdh
revers
transcript
reaction
use
intern
control
lane
normal
cell
bfa
poli
c
poli
c
bfa
pgml
poli
c
bfa
poli
c
bfa
amplif
without
templat
bp
ladder
concentr
poli
c
use
pgml
treatment
revers
ifninduc
inhibit
emcv
inhibit
viru
yield
cell
treat
variou
iuml
bfa
ktgml
dose
bfa
alon
inhibit
antivir
activ
ifn
assay
describ
previous
maheshwari
friedman
briefli
cell
grown
microtit
plate
confluent
treat
quadrupl
ifn
presenc
absenc
variou
dose
bfa
pgml
h
ifn
bfa
remov
cell
wash
infect
emcv
h
multipl
cell
unabsorb
viru
remov
cell
wash
fresh
medium
ad
cell
incub
h
examin
light
microscop
cytopath
effect
supernat
replic
well
pool
use
viru
yield
estim
data
plot
inhibit
viru
yield
compar
control
l
b
cell
treat
bfa
pgml
h
poli
c
pgml
ad
addit
h
total
cellular
rna
isol
rnazol
b
kit
teltest
inc
friendswood
tx
rna
purifi
lithium
chlorid
precipit
analyz
electrophoresi
denatur
formaldehyd
gel
ascertain
rna
undegrad
revers
transcript
perform
use
revers
transcriptas
rt
life
technolog
gaithersburg
md
random
primer
rt
mix
follow
compon
ad
pl
dntp
mix
mm
pl
pcr
buffer
pl
taq
polymeras
ui
pl
sens
primer
pgpl
pl
antisens
primer
pgpl
pl
distil
water
sampl
incub
dna
thermocycl
perkin
elmer
cetu
gene
amp
pcr
system
cycl
temperatur
cycl
follow
min
denatur
min
anneal
primer
min
primer
extens
confirm
equal
amount
rna
taken
pcr
reaction
experi
primer
housekeep
gene
glyceraldehyd
phosphat
dehydrogenas
gapdh
use
comparison
two
set
lb
cell
treat
ifnfl
iuml
andor
bfa
h
one
set
cell
infect
emcv
multipl
h
cellular
extract
infect
uninfect
cell
prepar
use
lysi
buffer
mm
hepe
ph
mm
magnesium
acet
mm
vv
mm
mercaptoethanol
contain
zgml
leupeptin
phenylmethylsulfonyl
fluorid
pmsf
protein
kinas
assay
done
describ
duboi
hovanessian
extract
briefli
cellular
extract
pg
protein
incub
poli
c
x
gml
atp
mm
mm
atp
cimmol
min
phosphoryl
reaction
stop
addit
x
sdsgel
sampl
buffer
heat
min
phosphoprotein
separ
sdspage
analyz
autoradiographi
depend
rnase
analyz
describ
nolansorden
et
al
bromid
substitut
radioact
deriv
p
p
aep
cp
use
probe
nucleas
probe
gener
gift
dr
robert
silverman
cleveland
clinic
foundat
cleveland
oh
cell
lyse
lysi
buffer
contain
gml
proteas
inhibitor
leupeptin
pmsf
lysat
centrifug
g
cellular
extract
g
protein
incub
probe
countsmin
min
ice
uv
light
addit
h
cross
link
reaction
mixtur
heat
min
sdsgel
sampl
buffer
protein
separ
sdspage
gel
dri
autoradiogram
prepar
use
xray
film
kodak
synthetas
present
x
g
supernat
fraction
bound
poli
poli
c
cellulos
method
stark
et
al
synthesi
determin
use
radiobind
method
knight
et
al
briefli
lysat
obtain
cell
centrifug
x
g
aliquot
supernat
contain
g
protein
made
dbg
mm
hepe
ph
mm
mm
magnesium
acet
mm
mercaptoethanol
vv
glycerol
buffer
wash
poli
c
cellulos
dbg
ad
aliquot
mixtur
incub
h
room
temperatur
supernat
remov
without
disturb
cellulos
cellulos
wash
twice
assay
mix
tl
dbg
mm
atp
ph
mm
ad
cellulos
incub
h
centrifug
supernat
assay
use
radiobind
assay
purifi
murin
cdna
kb
insert
synthetas
kindli
provid
dr
bryan
rg
william
cleveland
clinic
foundat
cleveland
oh
label
dctp
cimmol
random
primer
situ
hybrid
dctp
cimmol
klenow
enzym
northern
hybrid
la
cell
treat
bfa
gml
andor
ifnfl
iuml
overnight
cell
trypsin
adjust
concentr
x
cellsml
cell
suspens
collect
silan
activ
slide
cytospin
cytocentrifug
g
min
situ
hybrid
perform
describ
peltonen
et
al
slight
modif
briefli
slide
fix
paraformaldehyd
acetyl
min
dehydr
hybrid
h
hybrid
solut
contain
gml
cdna
probe
synthetas
mm
dithiothreitol
acetyl
bovin
serum
albumin
sodium
chlorid
deioniz
formamid
wv
dextran
sulfat
tgml
trna
polyvinylpyrrolidon
ficol
mm
edta
mm
trishcl
ph
posthybrid
perform
sequenti
incub
slide
progress
dilut
salinecitr
solut
mm
dithiothreitol
tritonx
dehydr
dip
emuls
autoradiographi
exposur
day
slide
develop
develop
stain
cresyl
violet
acet
mount
permount
cell
examin
photograph
zeiss
microscop
equip
camera
attach
rna
isol
phenolchloroform
extract
maniati
et
al
briefli
x
cell
wash
cold
pb
trypsin
use
trypsinedta
centrifug
rev
min
min
cell
lyse
use
cold
lysi
buffer
mm
mm
mm
ph
centrifug
supernat
rna
transfer
sdsbuffer
sd
mm
edta
mm
mm
ph
phenolchloroform
extract
repeat
time
aqueou
phase
rna
sodium
acet
vol
ethanol
ad
precipit
rna
overnight
rna
recov
centrifug
revmin
min
resuspend
depctreat
pl
vortex
store
rna
run
agaros
formaldehyd
denatur
gel
blot
onto
nytran
filter
overnight
probe
denatur
heat
min
quickli
cool
ice
probe
x
countsminml
ad
hybrid
solut
filter
incub
overnight
blot
wash
hybridizationwash
condit
use
stringent
expos
xray
film
autoradiogram
develop
shown
bfa
incub
cell
viru
infect
act
antivir
agent
sever
virus
howev
dose
bfa
cytotox
l
b
cell
demonstr
decreas
cell
number
uptak
thymidin
therefor
lower
dose
bfa
examin
cytotox
found
concentr
bfa
gml
cytotox
incub
h
cell
demonstr
cell
count
uptak
thymidin
data
shown
therefor
concentr
bfa
rang
use
studi
effect
viru
inhibit
presenc
ifn
report
dsrna
directli
induc
ifnfl
gene
fibroblast
memet
et
al
demonstr
whether
inhibit
ifninduc
gene
express
specif
ifninduc
gene
simpli
result
poor
metabol
cell
presenc
bfa
examin
induct
ifnfl
gene
poli
c
bfatreat
cell
undertaken
rtpcr
show
ifnfl
rna
still
induc
dsrna
presenc
bfa
fig
demonstr
cell
function
normal
bfa
incub
data
fig
show
ifn
exhibit
signific
antivir
activ
emcv
dosedepend
manner
antivir
effect
ifn
emcv
iuml
ifn
almost
satur
therefor
restrict
use
ifn
iuml
studi
variou
concentr
bfa
gml
use
studi
antivir
activ
emcv
bfa
revers
antivir
effect
ifn
emcv
howev
bfa
alon
antivir
activ
fig
sinc
much
differ
inhibit
antivir
activ
ifn
either
pgml
pgml
bfa
pgml
bfa
dosag
use
studi
pkr
strongli
phosphoryl
ifntreat
uninfect
fig
lane
emcvinfect
fig
lane
cellular
extract
compar
control
fig
fig
lane
bfatreat
fig
fig
lane
cell
bfa
inhibit
phosphoryl
pkr
ifn
bfa
treat
uninfect
fig
lane
emcvinfect
cell
fig
lane
northern
hybrid
analysi
synthetas
fig
show
detect
express
synthetas
control
bfa
treat
cell
synthetas
highli
express
ifn
iuml
treat
cell
fig
lane
fig
lane
howev
express
reduc
substanti
cell
treat
ifn
bfa
togeth
fig
lane
fig
lane
indic
bfa
downregul
ifn
induc
enzym
transcript
level
actin
fig
gapdh
fig
use
intern
control
verifi
initi
equal
quantiti
rna
integr
rna
prepar
situ
hybrid
show
express
synthetas
control
untreat
fig
bfatreat
fig
la
cell
synthetas
highli
express
evid
number
grain
present
ifntreat
cell
fig
fig
howev
express
significantli
reduc
cell
treat
ifn
bfa
fig
fig
correl
decreas
mrna
level
enzym
activ
synthetas
activ
determin
use
variou
dose
ifn
presenc
bfa
bfa
inhibit
synthetas
activ
induc
ifn
shown
fig
decreas
inhibit
activ
increas
ifn
dose
demonstr
bfa
could
complet
inhibit
induct
activ
synthesi
synthetas
mrna
inhibit
lesser
extent
enzym
activ
indic
bfa
may
exert
inhibitori
effect
transcript
posttranscript
level
data
fig
show
level
depend
rnase
uninfect
emcv
infect
b
lb
cell
signific
increas
activ
depend
rnase
found
cell
treat
iuml
ifnfl
lane
respect
compar
control
lane
well
bfatreat
lane
cell
bfa
treatment
uninfect
cell
along
ifn
significantli
reduc
level
depend
rnase
compar
ifn
alon
lane
howev
activ
depend
rnase
complet
inhibit
bfa
ifntreat
emcvinfect
cell
fig
lane
rais
question
whether
endogen
may
compet
probe
rule
presenc
endogen
cellular
extract
ifntreat
fig
lane
ifn
bfatreat
fig
lane
ifntreat
fig
lane
ifn
bfatreat
fig
lane
mix
examin
nucleas
present
inhibit
depend
rnase
mix
cellular
extract
could
expect
sever
fold
higher
ifntreat
cell
howev
level
nucleas
decreas
mix
cellular
extract
fig
lane
suggest
solubl
inhibitor
present
ifn
bfatreat
emcvinfect
cell
bfa
inhibit
glycosyl
export
protein
properti
bfa
led
explor
antivir
activ
virus
corona
viru
retroviru
pseudorabi
virus
alphavirus
requir
newli
synthes
glycosyl
secret
membran
bound
protein
infecti
cycl
tamura
et
al
dom
et
al
takatsuki
tamura
chen
et
al
cheung
et
al
wheali
et
al
maynel
et
al
bfa
effect
infecti
cycl
adenoviru
adenoviru
involv
glycoprotein
secret
infect
maynel
et
al
bfa
inhibit
replic
polioviru
nonenvelop
viru
possibl
prevent
format
vesicl
requir
rna
replic
present
studi
bfa
inhibit
emcv
nonenvelop
viru
similar
polioviru
studi
effect
bfa
polioviru
replic
bfa
present
medium
period
replic
viru
howev
present
studi
lower
concentr
bfa
use
remov
emcv
adsorpt
replic
discrep
inhibit
polioviru
emcv
bfa
may
due
bfa
dosag
incub
drug
viru
replic
cycl
mechan
ifn
inhibit
replic
virus
complet
understood
ifninduc
protein
kinas
synthetas
enzymat
pathway
describ
pestka
et
al
hovanessian
et
al
kerr
et
al
staeh
william
et
al
clemen
william
samuel
appear
involv
inhibit
replic
virus
interf
translat
viral
rna
pkr
highli
induc
mani
ifntreat
cell
hovanessian
upon
activ
dsrna
pkr
bind
atp
phosphoryl
catalys
phosphoryl
eukaryot
protein
synthesi
initi
factor
thu
mediat
inhibit
protein
synthesi
farrel
et
al
safer
emcv
infect
enhanc
phosphoryl
pkr
report
probabl
due
bind
replic
complex
emcv
aujean
et
al
levintow
data
report
paper
show
signific
increas
level
phosphoryl
pkr
ifntreat
uninfect
emcvinfect
lb
cell
bfa
treatment
along
ifn
inhibit
either
phosphoryl
express
pkr
ifntreat
cell
whether
emcvinfect
uninfect
therebi
suggest
overal
decreas
phosphoryl
thu
would
inhibit
viral
protein
synthesi
ifntreat
emcvinfect
cell
presenc
bfa
compar
cell
treat
ifn
alon
ifninduc
synthetas
system
includ
synthetas
latent
endonucleas
presenc
dsrna
synthetas
polymer
atp
activ
endonucleas
degrad
mrna
result
viral
protein
synthesi
inhibit
present
studi
northern
situ
hybrid
analysi
show
synthetas
gene
highli
express
ifntreat
cell
significantli
decreas
cell
bfa
sinc
synthetas
index
would
appear
concomit
reduct
level
lead
inhibit
activ
depend
rnase
level
depend
rnase
reduc
ifn
plu
bfatreat
cell
whether
infect
uninfect
compar
infect
uninfect
cell
treat
ifn
alon
loss
depend
nucleas
activ
monitor
loss
protein
presumpt
nucleas
directli
loss
activat
nucleas
cayley
et
al
mix
experi
fail
demonstr
presenc
solubl
inhibitor
nucleas
could
compet
bind
nucleas
inhibit
extract
therefor
decreas
depend
rnase
may
attribut
loss
nucleas
inactiv
bfa
overnight
use
first
set
rna
prepar
blot
hybrid
synthetas
probe
autoradiogram
scan
inhibit
transcript
obtain
cellular
lysat
obtain
second
set
activ
enzym
obtain
use
radiobind
assay
dose
ifn
presenc
bfa
data
plot
find
whether
inhibit
enzym
bfa
transcript
posttranscript
level
research
tion
support
data
show
decreas
effect
bfa
revers
ifn
induc
inhibit
emcv
synthetas
higher
initi
dose
ifn
